Age-related macular degeneration (AMD) is fast becoming a public health problem all over the world. AMD can be of two types: Wet AMD and dry AMD. Wet AMD is a result of choroidal neovascularisation beneath the retina with resultant exudation, haemorrhages and finally scarring. Dry AMD is characterised by retinal pigment epithelium atrophy and also retinal atrophy. Apart from age, environmental, metabolic and genetic factors also play role in this disease. Continued research over last two decades on pathogenesis of AMD helped to develop appropriate therapeutic targets. With various landmark clinical trials conducted in last two decades, antivascular endothelial growth factor (anti-VEGF) drugs have emerged as the most effective treatment in wet AMD. The management of dry AMD is a challenge for care-givers worldwide due to the lack of effective therapies. The current strategy may be outlined as follows: Lifestyle modification, anti-oxidant supplementation, supportive measures. These measures have been proved to be effective in improving the quality of life of AMD patients.